Suzetrigin: A Novel Pain Medication with Potential for the Swiss Market
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to severe acute pain in adults. It was developed by Vertex Pharmaceuticals and represents the first new class of pain medications in over two decades.
Suzetrigin works by selectively inhibiting the voltage-gated sodium channel NaV1.8, which is primarily expressed in peripheral pain-sensing neurons. By specifically blocking this channel, Suzetrigin modulates pain transmission without affecting the central nervous system, thereby avoiding the risk of dependence commonly associated with opioid-based pain medications.
In clinical trials, Suzetrigin demonstrated significant pain reduction compared to placebo but was not more effective than opioids. Common side effects include itching, muscle cramps, skin rash, and elevated creatine kinase levels.
Although Suzetrigin has already been approved in the United States, approval by the European Medicines Agency (EMA)—and thus in Switzerland—is still pending. Given the global efforts to find alternatives to opioid-based pain medications, Suzetrigin could play a significant role in the future of pain management.
The introduction of Suzetrigin in Switzerland would offer a new treatment option for patients with acute pain, particularly for those at risk of opioid dependence or for whom NSAIDs are contraindicated.
Suzetrigin represents a promising advancement in pharmacological pain management. Its novel mechanism of action and lack of dependence potential make it an attractive alternative to existing pain medications. Future approval in Switzerland could offer patients and healthcare providers a valuable new option for the treatment of acute pain.
However, it is important to note that the FDA approval is based on only two studies, both of which focus solely on its use for acute—not chronic—pain. Due to the limited number of cases studied, conclusions regarding its efficacy across different areas of pain management remain restricted.
Subscribe to Newsletter
We’d be happy to share more about us and our services in the next newsletter and on www.issz.ch.
Current Affairs
Further News & Publications
Adjuvant Thermal Radiofrequency Treatment
Thermal radiofrequency denervation (RFD) is an established, minimally invasive procedure for the treatment of chronic low back pain when it originates from the facet joints.
Low-Dose Naltrexone (LDN)
Low-Dose Naltrexone (LDN) is a well-tolerated medication used to relieve chronic pain, particularly in cases of fibromyalgia and immune dysregulation. In addition to pain relief,
Neuroablative Procedures Briefly Explained
Through targeted ablation, commonly referred to as “nerve cauterization,” pain signal transmission from a specific body region to the central nervous system (brain and spinal
Modern imaging in pain medicine cloud based with PACSonWEB
In interventional pain medicine reliable access to imaging procedures such as ultrasound or BV X ray devices is essential. From the very beginning we decided
Lecture activity in the field of pain medicine
Lecture activity in the field of pain medicine The continuous sharing of specialist knowledge and the exchange with colleagues from various medical disciplines are a
Dr Marios Moniatis strengthens the ISSZ team
We are delighted to welcome Dr Marios Moniatis to our team Dr Marios Moniatis is a board-certified specialist in anaesthesiology (FMH) and a certified expert
Adjuvant Thermal Radiofrequency Treatment
Thermal radiofrequency denervation (RFD) is an established, minimally invasive procedure for the treatment of chronic low back pain when it originates from the facet joints.
Low-Dose Naltrexone (LDN)
Low-Dose Naltrexone (LDN) is a well-tolerated medication used to relieve chronic pain, particularly in cases of fibromyalgia and immune dysregulation. In addition to pain relief,
Neuroablative Procedures Briefly Explained
Through targeted ablation, commonly referred to as “nerve cauterization,” pain signal transmission from a specific body region to the central nervous system (brain and spinal
Modern imaging in pain medicine cloud based with PACSonWEB
In interventional pain medicine reliable access to imaging procedures such as ultrasound or BV X ray devices is essential. From the very beginning we decided
Lecture activity in the field of pain medicine
Lecture activity in the field of pain medicine The continuous sharing of specialist knowledge and the exchange with colleagues from various medical disciplines are a
Dr Marios Moniatis strengthens the ISSZ team
We are delighted to welcome Dr Marios Moniatis to our team Dr Marios Moniatis is a board-certified specialist in anaesthesiology (FMH) and a certified expert